Scarica l'app Stockscreener
1.83
2.66%
-0.05
Precedente Chiudi:
$1.88
Aprire:
$1.89
Volume 24 ore:
107.52K
Relative Volume:
0.12
Capitalizzazione di mercato:
$4.14M
Reddito:
-
Utile/perdita netta:
$-16.77M
Rapporto P/E:
-0.0524
EPS:
-34.9387
Flusso di cassa netto:
$-15.08M
1 W Prestazione:
-2.66%
1M Prestazione:
-8.50%
6M Prestazione:
-79.53%
1 anno Prestazione:
-89.30%
Intervallo 1D:
$1.81
$1.89
Intervallo di 1 settimana:
$1.81
$1.97
Portata 52W:
$1.71
$55.00
Genprex Inc Stock (GNPX) Company Profile
Nome
Genprex Inc
Settore
Industria
Telefono
512-537-7997
Indirizzo
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
1.8216 | 4.27M | 0 | -16.77M | -15.08M | -34.94 |
VRTX
Vertex Pharmaceuticals Inc
|
437.09 | 115.27B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
742.51 | 80.00B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
699.18 | 43.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.80 | 43.52B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.48 | 30.74B | 5.36B | 287.73M | 924.18M | 2.5229 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-26 | Iniziato | National Securities | Buy |
| 2019-04-29 | Iniziato | Noble Capital Markets | Outperform |
Genprex Inc Borsa (GNPX) Ultime notizie
IPO Launch: Whats the beta of Genprex Inc stock2026 Drop Watch & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Dip Buying: Will Genprex Inc benefit from green energy policiesQuarterly Profit Review & Free Long-Term Investment Growth Plans - baoquankhu1.vn
GNPX Stock Chart | GENPREX INC (NASDAQ:GNPX) - ChartMill
Performance Recap: What are the analyst revisions for Guess IncIs Genprex Inc stock a good investment in YEAR2026 Selloffs & Weekly Chart Analysis and Guides - baoquankhu1.vn
Genprex, Inc.: Fundamental Analysis and Financial Ratings | 2DE | US3724463027 - marketscreener.com
GNPX Earnings History & Surprises | EPS & Revenue Results | GENPREX INC (NASDAQ:GNPX) - ChartMill
Genprex collaborators to present lung cancer data at AACR meeting By Investing.com - Investing.com South Africa
Genprex presents positive preclinical REQORSA data at AACR showing biomarkers and combo efficacy - TradingView
Genprex Highlights New Reqorsa Preclinical Data at AACR - TipRanks
GNPX: Genprex Researchers to Present at AACR 2026 with Promising Lung Cancer Data - GuruFocus
Genprex collaborators to present lung cancer data at AACR meeting - Investing.com
Genprex (NASDAQ: GNPX) posts positive preclinical data on REQORSA in NSCLC - Stock Titan
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting - PR Newswire
New Highs: Will Genprex Inc benefit from green energy policiesTrade Risk Assessment & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
GNPX Technical Analysis | Trend, Signals & Chart Patterns | GENPREX INC (NASDAQ:GNPX) - ChartMill
Genprex to Participate at BIO Europe Spring 2026 - marketscreener.com
GNPX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aug Closing: Will Genprex Inc outperform tech stocksMarket Activity Report & Weekly High Return Forecasts - baoquankhu1.vn
Trend Recap: Will Genprex Inc outperform tech stocksWeekly Gains Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Genprex receives patent approval in Australia for cancer therapy - Investing.com Nigeria
Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying - Yahoo Finance
GNPX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Genprex (NASDAQ: GNPX) CMO has shares withheld to cover RSU taxes - Stock Titan
Genprex (GNPX) CEO reports 9,330-share tax-withholding disposition - Stock Titan
Congressional Trading Activity Insights - Intellectia AI
Genprex bags major patent wins in Japan & Europe for REQORSA cancer therapy - Indian Pharma Post
Genprex Advances Cancer Therapy Strategy with Key International Patents - AD HOC NEWS
Genprex receives Japanese and European patents for cancer therapy By Investing.com - Investing.com India
Genprex stock jumps on Japan, Europe patent approvals By Investing.com - Investing.com Nigeria
Genprex stock jumps on Japan, Europe patent approvals - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Genprex (GNPX) Gains Global Patent Approvals for Innovative Canc - GuruFocus
Genprex Secures Key Global Patents for REQORSA Therapy - TipRanks
Genprex receives Japanese and European patents for cancer therapy - Investing.com
Genprex secures Japan, EU patents for REQORSA combos, bolstering Acclaim-3 IP and trial - TradingView
New cancer patents support Genprex (NASDAQ: GNPX) Acclaim-3 trial - Stock Titan
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer - Barchart.com
Genprex Navigates a Pivotal Juncture Amid Clinical Progress and Financial Strain - AD HOC NEWS
Published on: 2026-02-21 03:40:37 - baoquankhu1.vn
Will Genprex Inc. benefit from green energy policiesChart Signals & Accurate Trade Setup Notifications - mfd.ru
How strong is Genprex Inc. (2DE0) stock earnings growth2025 Short Interest & Precise Swing Trade Entry Alerts - mfd.ru
Genprex receives patent approval in Australia for cancer therapy By Investing.com - Investing.com Canada
Ayrton Capital-led group reports 9.72% Genprex (GNPX) stake via warrants - Stock Titan
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers - BioSpace
Genprex (GNPX) Gains Australian Patent Approval for Cancer Treat - GuruFocus
Genprex Gains Australian Patent Acceptance for REQORSA Therapy - TipRanks
Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy - TradingView
Genprex Patent Acceptance and Clinical Trial Expansion - TradingView
Genprex (NASDAQ: GNPX) advances REQORSA patent strategy and expands Acclaim-3 lung cancer trial - Stock Titan
Bull Run: Will Genprex Inc benefit from green energy policiesPortfolio Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Genprex Inc Azioni (GNPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.23%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):